https://doi.org/10.4081/itjm.2020.1290
Antirheumatic in SARS-CoV-2: benefit or risk?
Submitted: 15 April 2020
Accepted: 28 April 2020
Published: 29 April 2020
Accepted: 28 April 2020
Abstract Views: 1762
PDF: 489
HTML: 6
HTML: 6
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Authors
Not available
Downloads
Download data is not yet available.
PlumX Metrics
PlumX Metrics provide insights into the ways people interact with individual pieces of research output (articles, conference proceedings, book chapters, and many more) in the online environment. Examples include, when research is mentioned in the news or is tweeted about. Collectively known as PlumX Metrics, these metrics are divided into five categories to help make sense of the huge amounts of data involved and to enable analysis by comparing like with like.
Citations
How to Cite
Ferrara, F. (2020). Antirheumatic in SARS-CoV-2: benefit or risk?. Italian Journal of Medicine, 14(2), 114–115. https://doi.org/10.4081/itjm.2020.1290
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.